Introduction {#s1}
============

Atrial fibrillation (AF) is the most common arrhythmia in humans, characterized by irregularly irregular atrial electrical activity, resulting in asynchronous atrial contraction. AF is a global problem, affecting more than 33 million people and approximately 25% of Americans over the age of forty ([@bib39]; [@bib48]). AF is associated with significant morbidity and mortality due to thromboembolic events, heart failure, and sudden cardiac death. AF also significantly complicates overall health care management, with AF patients costing five times more to treat than patients without AF ([@bib2]). The total annual cost to treat AF patients in the US is on the order of 26 billion dollars ([@bib39]). AF is a highly significant and growing public health concern.

A genetic basis for AF risk has been described in the last decade. Large community-based cohort studies indicate that heritability provides between 40% and 62% of AF risk ([@bib39]; [@bib11]). An emerging paradigm describes AF as a multifactorial disease with genetic predisposition that will determine the propensity of secondary clinical insults to cause AF. This model highlights the importance of understanding the molecular mechanisms underlying the genetic predisposition to AF. Genome-wide association studies (GWAS) studies have identified common risk variants and familial mutations at the T-box transcription factor 5 (TBX5) locus that result in increased risk for AF ([@bib35]; [@bib43]). Adult-specific *Tbx5* knockout mice demonstrate primary spontaneous and sustained AF, providing evidence supporting the genetic implication at this locus. GWAS have also implicated multiple genes involved in cardiomyocyte calcium handling, including *Atp2a2*, encoding the sarcolemmal calcium ATPase SERCA2, and *Sln* and *Pln*, encoding direct binding SERCA2 inhibitors sarcolipin and phospholamban, respectively. We have previously demonstrated that these cardiomyocyte calcium control genes are direct TBX5 targets ([@bib36]). These observations suggested that tight transcriptional control of SERCA2 activity may be central to atrial rhythm robustness and that variation in SERCA2 expression and activity may contribute to AF risk.

The cellular mechanisms causing the irregular electrical activity in AF are believed to include an abnormal myocardial substrate and formation of an ectopic trigger. Abnormal substrate refers to altered electrical conduction between cardiomyocytes. Ectopic trigger refers to cardiomyocyte ectopy, or initiation of electrical activity at regions outside of the sinoatrial node. Both of these cellular phenomena are observed in *Tbx5* adult-specific mutant mice and have been associated with abnormal cellular calcium handling ([@bib14]; [@bib46]; [@bib47]; [@bib45]; [@bib41]; [@bib38]; [@bib34]; [@bib29]; [@bib27]; [@bib23]; [@bib21]; [@bib15]; [@bib8]). We described the TBX5-dependent gene regulatory network essential for atrial rhythm control and identified downstream ion channels and transporters potentially important to rhythm control ([@bib36]; [@bib50]). Triggered activity in the form of early and delayed afterdepolarizations (EADs and DADs) observed in Tbx5-deficient atrial cardiomyocytes could be rescued by heavy buffering of cytoplasmic calcium ([@bib36]). *Tbx5*-dependent calcium handling has thereby emerged as a potential mediator of the myocardial physiologic abnormalities resulting in AF.

We sought to define the Tbx5-dependent cellular mechanisms responsible for abnormal calcium-dependent electrical activity. We found that *Tbx5*-dependent AF is associated with abnormal sarcoplasmic reticulum (SR) calcium uptake due to depressed SERCA2 expression, depressed SERCA function, and increased phospholamban expression. Decreased SR calcium uptake is compensated by increased Ca^2+^ extrusion from cardiomyocytes via sodium-calcium exchanger (NCX) current (I~NCX~), which provides a mechanism for TBX5-dependent action potential (AP) prolongation and the propensity for triggered cellular ectopy. In the setting of enhanced NCX mediated Ca^2+^ efflux and depressed SR uptake, compensatory increases in L-type calcium current (I~CaL~) balance calcium extrusion to maintain steady state calcium homeostasis. Together these calcium handling alterations contribute to AP prolongation and triggered activity.

We further demonstrated that calcium handling abnormalities, AP alterations, and triggered activity are all normalized by knockout of phospholamban, which prevents *Tbx5*-dependent AF. These results establish a direct link between depressed SR Ca^2+^ sequestration, enhanced NCX activity, and AF. This model suggests that targeting calcium handling pathways may be a treatment approach for a subpopulation of AF patients.

Results {#s2}
=======

Cytoplasmic calcium is responsible for AP prolongation in *Tbx5*-mutant atrial cardiomyocytes {#s2-1}
---------------------------------------------------------------------------------------------

We previously reported that *Tbx5*-deficient atrial cardiomyocytes demonstrated AP prolongation and myocardial ectopy. We hypothesized that these defects were caused by cellular calcium handling abnormalities. We therefore surveyed the expression of known calcium handling genes in the adult-specific *Tbx5* knockout model. We assessed gene expression in *Tbx5^fl/fl^;R26^CreERT2^* and control *R26^CreERT2^* mice at 10 weeks of age following tamoxifen (TM) treatment at 8 weeks of age. Consistent with previous observations, the adult *Tbx5^fl/fl^;R26^CreERT2^* but not control mice developed spontaneous AF, showing an irregularly irregular heartbeat, by telemetric electrocardiogram (ECG) recordings ([Figure 1A,B](#fig1){ref-type="fig"}). As previously shown, APs and \[Ca\]~i~ transients were prolonged in *Tbx5^fl/fl^;R26^CreERT2^* ([Figure 1C](#fig1){ref-type="fig"}) ([@bib36]). We assessed expression of genes important to cellular calcium handling in the left atrium by quantitative PCR ([Figure 1D](#fig1){ref-type="fig"}). mRNA transcripts for RyR2 (*Ryr2*) and SERCA2 (*Atp2a2*), two of the main determinants of sarcoplasmic reticulum (SR) calcium flux, were decreased by 61% and 71% respectively in *Tbx5^fl/fl^;R26^CreERT2^* mice compared to *R26^CreERT2^* controls (p=0.026 and p=0.001 for *Ryr2* and *Atp2a2* respectively) consistent with previous studies ([@bib36]). In addition, phospholamban (*Pln*) mRNA expression was increased by 69% in *Tbx5^fl/fl^;R26^CreERT2^* compared to *R26^CreERT2^* (p=0.023), which would be expected to further depress SERCA2 activity. There was no significant difference in mRNA expression of the alpha 1C subunit of the L-type calcium channel (*Cacna1c*), the cardiac sodium calcium exchanger (*Ncx1*), or any of the calmodulins 1--3 (*Calm1, Calm2, Calm3*) ([Figure 1C](#fig1){ref-type="fig"}). These data are consistent with the hypothesis that the myocardial electrophysiology deficits in the *Tbx5*-deficient AF model may be due to abnormal calcium handling.

![Atrial fibrillation in *Tbx5^fl/fl^;R26^CreERT2^* mice is associated with altered expression of genes important to cellular calcium handling.\
(**A**) *Tbx5^fl/fl^;R26^CreERT2^* mice developed spontaneous AF as assessed by surface ECG compared to *R26^CreERT2^.* Traces are representative of 15 animals per genotype. (**B**) Poincaré plot shows irregularly irregular rhythm in *Tbx5^fl/fl^;R26^CreERT2^*, consistent with AF, compared to normal sinus rhythm in *R26^CreERT2^* mice. Poincaré plots are each from one animal, andrepresentative of 15 animals per genotype. (**C**) Simultaneous AP and \[Ca\]~i~ recordings show prolonged AP duration and slowed \[Ca^2+^\]~i~ transient decay in *Tbx5^fl/fl^;R26^CreERT2^* atrial cardiomyocytes compared to *R26^CreERT2^*. Recordings are representative of simultaneous \[Ca\]~i~ and E~m~ recordings (myocytes/mice; dual E~m~ and \[Ca\]~i~ from 5/5 *R26^CreERT2^* and 17/5 *Tbx5^fl/fl^;R26^CreERT2^*, E~m~ only from 23/9 *R26^CreERT2^* and 20/9 *Tbx5^fl/fl^;R26^CreERT2^*, and \[Ca\]~i~ only from 27/6 *R26^CreERT2^* and 28/6 *Tbx5^fl/fl^;R26^CreERT2^*). (**D**) Quantitative PCR was performed on RNA isolated from left atrial tissue of 3--5 animals per genotype. mRNA expression of a panel of calcium handling genes potentially important for rhythm regulation was determined. *Ryr2* and *Atp2a2* expression were decreased and *Pln* expression was increased in *Tbx5^fl/fl^;R26^CreERT2^* relative to *R26^CreERT2^* atria. (\*\*\*p\<0.001, \*\*, p\<0.01, \*, p\<0.05).\
10.7554/eLife.41814.005Figure 1---source data 1.qPCR data for [Figure 1D](#fig1){ref-type="fig"}.](elife-41814-fig1){#fig1}

We examined the relationship between myocardial electrophysiology deficits and calcium flux in *Tbx5*-mutant atria. In steady state, with each cardiomyocyte contraction cycle, calcium entering the cardiomyocyte (L-type calcium channel, I~CaL~) is extruded from the cell (predominantly via inward I~NCX~). Similarly, calcium leaving the SR via RyR2 release or SR leak pathways is taken back up into the SR via SERCA2. We examined the effect of altered TBX5-dependent gene expression on these aspects of cardiomyocyte calcium flux. Given the observed changes in *Ryr2* and *Atp2a2* mRNA abundance, we hypothesized that AP prolongation in *Tbx5* deficient cardiomyocytes was due to calcium handling defects downstream of initial Ca^2+^ entry through I~CaL~. To test this, we recorded APs in the presence and absence of the L-type Ca^2+^ channel blocker nifedipine. This approach blocks Ca^2+^ entry into the cell and indirectly removes the effect of Ca^2+^ entry on downstream Ca^2+^ handling pathways, including SR Ca^2+^ release/reuptake as well as the electrogenic effect of calcium transport out of the cell via inward I~NCX~. 30 μM nifedipine completely inhibited L-type calcium current, preventing Ca^2+^ entry or release of SR calcium in control *R26^CreERT2^* and *Tbx5^fl/fl^;R26^CreERT2^* ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In control *R26^CreERT2^* atrial cardiomyocytes, the effect of nifedipine on AP duration (APD) was small, with 19 ± 4% shortening of APD at 90% repolarization (APD90) (p=0.008) ([Figure 2A](#fig2){ref-type="fig"}). However, in *Tbx5^fl/fl^;R26^CreERT2^* atrial cardiomyocytes, nifedipine had a profound effect: APD at 50% repolarization (APD50) was shortened by 16 ± 6% and APD90 by 61 ± 6% (p=0.02 and 0.007 respectively) ([Figure 2B,C](#fig2){ref-type="fig"}). Western blot with densitometry analysis for Ca~V~1.2 showed no significant difference in protein expression ([Figure 2D](#fig2){ref-type="fig"}), in line with the qPCR data ([Figure 1D](#fig1){ref-type="fig"}), consistent with no TBX5-driven direct transcriptional regulation of L-type calcium channels. However, peak I~CaL~ current was increased 92 ± 34% (p=0.027) in *Tbx5^fl/fl^;R26^CreERT2^* atrial cardiomyocytes compared to control *R26^CreERT2^* ([Figure 2E and F](#fig2){ref-type="fig"}). The inactivation kinetics at peak I~CaL~ were accelerated *Tbx5^fl/fl^;R26^CreERT2^* compared to control *R26^CreERT2^* ( τ = 26.7 ± 3.4 ms *vs*. τ = 40.0 ± 3.0 ms; p=0.05). Steady-state I~CaL~ inactivation was unchanged ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). These data suggest that increased I~CaL~ may contribute to TBX5-loss associated AP prolongation and EADs. However, nifedipine also blocks SR Ca^2+^ release as well as downstream Ca^2+^ extrusion pathways, which also affect AP duration. Further, since late AP repolarization is dramatically prolonged (negative to −30 mV where I~CaL~ is largely inactive) we hypothesized that *Tbx5*-deficiency disrupts Ca^2+^ handling pathways downstream of I~CaL~.

![Calcium current blockade dramatically shortened the AP in *Tbx5^fl/fl^;R26^CreERT2^* atrial cardiomyocytes, consistent with the \[Ca\]~i~ dependence of AP prolongation following TBX5 loss.\
(**A**) Representative recording of an AP from *R26^CreERT2^* atrial cardiomyocytes before and after 30 µM nifedipine treatment. (**B**) Representative recording of a *Tbx5^fl/fl^;R26^CreERT2^* atrial cardiomyocytes before and after nifedipine treatment. (**C**) Paired APD properties before and after treatment with 30 µM nifedipine (myocytes/mice; n = 8/3*Tbx5^fl/fl^;R26^CreERT2^* and n = 6/4 *R26^CreERT2^)*. In *R26^CreERT2^* cardiomyocytes, the effect of nifedipine on APD90 was small, but significant 19 ± 4%. A much larger nifedipine effect was observed in *Tbx5^fl/fl^;R26^CreERT2^* cardiomyocytes. APD50 decreased by 16 ± 6% and APD90 decreased by 61 ± 6% in the presence of nifedipine. (**D**) Western blot of atrial tissue in five animals for each genotype showed protein expression for the alpha 1C subunit of the L-type calcium channel (Ca~v~1.2) was unchanged. (normalized to GAPDH) (**E,F**) Representative I~CaL~ recordings show Peak L-type calcium current was increased in *Tbx5^fl/fl^;R26^CreERT2^* cardiomyocytes compared to *R26^CreERT2^* (**G**) Average IV relationship of L-type calcium current (myocytes/mice; n = 22/7 *R26^CreERT2^* and 20/5 *Tbx5^fl/fl^;R26^CreERT2^*). (\*\*\*p\<0.001, \*\*, p\<0.01, \*, p≤0.05).\
10.7554/eLife.41814.010Figure 2---source data 1.AP and I~CaL~ parameters for [Figure 2C,G](#fig2){ref-type="fig"}.\
10.7554/eLife.41814.011Figure 2---source data 2.Western blot for [Figure 2D](#fig2){ref-type="fig"}.](elife-41814-fig2){#fig2}

Removal of *Tbx5* results in decreased Ca^2+^ sparks and RyR2 expression, but no overall reduction in RyR2 open probability {#s2-2}
---------------------------------------------------------------------------------------------------------------------------

Because RyR2 is a critically important sarcolemmal calcium extrusion channel and *Ryr2* mRNA was downregulated in *Tbx5*-mutant atria, we investigated the *Tbx5* dependent regulation of RyR2 protein expression and function. RyR2 protein expression was significantly decreased in left atria of *Tbx5^fl/fl^;R26^CreERT2^* mice compared to *R26^CreERT2^* mice by western blot ([Figure 3A](#fig3){ref-type="fig"}), consistent with the observed downregulation of *Ryr2* mRNA ([Figure 1B](#fig1){ref-type="fig"}). We hypothesized that decreased RyR2 contributed to abnormal Ca^2+^ release from the SR and tested this by measuring local spontaneous RyR2-mediated Ca^2+^ release events (Ca^2+^ sparks) using confocal linescans ([Figure 3B](#fig3){ref-type="fig"}). The frequency of Ca^2+^ sparks in *Tbx5^fl/fl^;R26^CreERT2^* atrial cardiomyocytes was decreased in comparison with *R26^CreERT2^* atrial cardiomyocytes at different pacing frequencies from 0 to 2 Hz ([Figure 3C](#fig3){ref-type="fig"}). A decrease in calcium sparks can be due to either decreased RyR2 open probability or a reduced SR calcium load. To differentiate these possibilities, we first examined RyR2 function in the setting of reduced RYR2 expression by performing a \[^3^H\]-ryanodine binding assay. \[^3^H\]-ryanodine binding to RyR2 correlates with RyR2 open probability ([@bib14]). Despite reduced ryanodine receptor expression, overall ryanodine binding was unchanged over the majority of the physiological range of calcium values, with no shift in calcium sensitivity ([Figure 3D](#fig3){ref-type="fig"}). This observation suggests that the alterations in spark frequency were not due to changes in total RyR2 open probability. Instead, it may be caused by diminished SR Ca^2+^ uptake, a SERCA-dependent property.

![Spark frequency is reduced in *Tbx5^fl/fl^;R26^CreERT2^* atrial cardiomyocytes.\
(**A**) Western blot from atrial tissue from 10 animals per genotype was used to measure RyR2 expression. RyR2 was significantly decreased in *Tbx5^fl/fl^;R26^CreERT2^* atria compared to *R26^CreERT2^* atria (normalized to GAPDH). (**B**) Fluo-4 loaded cardiomyocytes demonstrated reduced spark frequency in *Tbx5^fl/fl^;R26^CreERT2^* compared to *R26^CreERT2^* atrial cardiomyocytes (representative recordings). (**C**) Spark frequency was reduced at rest and after steady state pacing at different frequencies (myocytes/mice; n = 12/4 *Tbx5^fl/fl^;R26^CreERT2^* and n = 12/3 *R26^CreERT2^*). (**D**) Ryanodine binding assay (without normalization) demonstrated no significant difference over the physiologic range of \[Ca\]~i~ in *Tbx5^fl/fl^;R26^CreERT2^* compared to *R26^CreERT2^* ([@bib48]). Each measure corresponds to an assay performed on pooled atria from 8 to 10 mice with three independent measures per condition (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001).\
10.7554/eLife.41814.013Figure 3---source data 1.Western blot for [Figure 3A](#fig3){ref-type="fig"}.\
10.7554/eLife.41814.014Figure 3---source data 2.Spark analysis for [Figure 3C](#fig3){ref-type="fig"}.\
10.7554/eLife.41814.015Figure 3---source data 3.Ryanodine binding assay for [Figure 3D](#fig3){ref-type="fig"}.](elife-41814-fig3){#fig3}

Adult-specific *Tbx5* deficiency reduces SERCA activity and SR load while increasing sodium-calcium exchanger activity {#s2-3}
----------------------------------------------------------------------------------------------------------------------

We next focused on the balance of diastolic calcium efflux pathways as potential mediators of Ca^2+^ mishandling by measuring SR Ca^2+^ content and protein expression and function of SERCA2 and NCX1. We observed that SERCA2 protein expression was decreased while NCX1 protein expression was increased in *Tbx5^fl/fl^;R26^CreERT2^* in comparison with *R26^CreERT2^* atria ([Figure 4A,B](#fig4){ref-type="fig"}). To define steady state SR Ca^2+^ content, we loaded cardiomyocytes with Fluo-4 AM and paced with a train of field stimuli to achieve a steady state Ca^2+^ content, peak Ca^2+^ content, and rate of Ca^2+^ removal were measured ([Figure 4C,D](#fig4){ref-type="fig"}). The \[Ca^2+^\]~i~ transient peaks were unchanged, but \[Ca^2+^\]~i~ transient decay rates, corresponding to SR Ca^2+^ uptake and cellular Ca^2+^ extrusion, were slowed in *Tbx5^fl/fl^;R26^CreERT2^* compared to *R26^CreERT2^* atrial cardiomyocytes ([Figure 4E,F](#fig4){ref-type="fig"}) ([@bib36]), consistent with defective Ca^2+^ removal from the cytosol. We also measured \[Ca^2+^\]~i~ transients in voltage clamp mode using 40 ms square wave voltage clamp pulses from −80 to 0 mV ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Similar to the field stimulation experiments, \[Ca^2+^\]~i~ transient decay rates were slowed, but \[Ca^2+^\]~i~ transient peaks were decreased by 23 ± 4% (p=0.02) in *Tbx5^fl/fl^;R26^CreERT2^* cardiomyocytes compared to *R26^CreERT2^*, which suggests that AP prolongation is essential to maintaining peak twitch \[Ca^2+^\]~i.~ The latter experiment is also consistent with depressed SR loads in *Tbx5^fl/fl^;R26^CreERT2^* compared to *R26^CreERT2^* atrial myocytes.

![SERCA function is decreased while NCX function is increased in *Tbx5^fl/fl^;R26^CreERT2^* atrial cardiomyocytes.\
(**A**) Expression of SERCA2 was significantly decreased (normalized to GAPDH) while (**B**) expression of NCX1 was significantly increased in *Tbx5^fl/fl^;R26^CreERT2^* atria compared to *R26^CreERT2^* atria as measured by western blot in 10 animals per genotype. (normalized to GAPDH) (**C**) Application of Na^+^ free caffeine solution after pacing to steady state at 1 Hz provided a measurement of SR load. In the absence of extracellular Na^+^, \[Ca^2+^\]~i~ plateaued at high levels due to negligible role of non-NCX mediated extrusion in *R26^CreERT2^* and *Tbx5^fl/fl^;R26^CreERT2^* atrial cardiomyocytes. Removal of caffeine in the absence of external Na^+^ provided a measure of SERCA mediated SR calcium uptake (representative traces). (**D**) Restoration of external Na^+^, in the presence of sustained extracellular caffeine provided a measure of NCX mediated calcium efflux (representative traces). (**E**) The peak of steady state twitch \[Ca^2+^\]~i~ transients was similar but (**F**) tau of \[Ca^2+^\]~i~ decay, determined from twitch \[Ca^2+^\]~i~ transients, was increased in *Tbx5^fl/fl^;R26^CreERT2^* compared to *R26^CreERT2^* cardiomyocytes (myocytes/mice; n = 27/6 *R26^CreERT2^, n = 28/6 Tbx5^fl/fl^;R26^CreERT2^)*. (**G**) SR load, determined from peak caffeine transients was decreased in *Tbx5^fl/fl^;R26^CreERT2^* compared to R26^CreERT2^ cardiomyocytes (myocytes/mice; n = 34/*6 R26^CreERT2^, n = 32/6 Tbx5^fl/fl^;R26^CreERT2^*). (**H**) SERCA activity, determined from the maximal rate of calcium decay was diminished in *Tbx5^fl/fl^;R26^CreERT2^* compared to *R26^CreERT2^* cardiomyocytes (myocytes/mice; n = 29*/3 R26^CreERT2^, n = 32/3 Tbx5^fl/fl^;R26^CreERT2^*). (**I**) NCX activity (decay slope), was increased at all levels of calcium in *Tbx5^fl/fl^;R26^CreERT2^* cardiomyocytes (myocytes/mice; n = 35*/3 R26^CreERT2^, n = 21/3 Tbx5^fl/fl^;R26^CreERT2^)*. (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001).\
10.7554/eLife.41814.019Figure 4---source data 1.Western blot for [Figure 4A,B](#fig4){ref-type="fig"}.\
10.7554/eLife.41814.020Figure 4---source data 2.Ca^2+^ handling parameters for [Figure 4E--H](#fig4){ref-type="fig"}.\
10.7554/eLife.41814.021Figure 4---source data 3.NCX activity for [Figure 4I](#fig4){ref-type="fig"}.](elife-41814-fig4){#fig4}

We hypothesized that decreased SERCA2 expression caused decreased SR load. We examined SERCA activity by synchronizing the opening of RyR2 channels while preventing Ca^2+^ extrusion through NCX using caffeine containing, sodium-free, Tyrode solution. This provides a measurement of the maximum release of Ca^2+^ into the cytosol from the SR, a measure of the SR Ca^2+^ load ([Figure 4C,D](#fig4){ref-type="fig"}). SR \[Ca^2+^\] was reduced by 24 ± 8% (p=0.0005) in *Tbx5^fl/fl^;R26^CreERT2^* compared with *R26^CreERT2^* atrial cardiomyocytes ([Figure 4G](#fig4){ref-type="fig"}). SERCA activity was assessed from \[Ca^2+^\]~i~ decay rate after SR release in the absence of external sodium (NCX inactive). Peak SERCA activity was reduced by 31 ± 9% (p=0.006) in *Tbx5^fl/fl^;R26^CreERT2^* compared with *R26^CreERT2^* atrial cardiomyocytes ([Figure 4C,H](#fig4){ref-type="fig"}). NCX activity was assessed as the rate of change in \[Ca^2+^\]~i~ decay in Na^+^ containing caffeine solution, preventing net SR uptake. Since NCX activity depends on \[Ca\]~i~, we plotted NCX as a function of the \[Ca\]~i~ signal. NCX activity was \~60% higher in *Tbx5^fl/fl^;R26^CreERT2^* in comparison with *R26^CreERT2^* atrial cardiomyocytes ([Figure 4D,I](#fig4){ref-type="fig"}). Thus, removal of *Tbx5* causes decreased SR Ca^2+^ load and decreased SERCA function, but increased NCX mediated Ca^2+^ extrusion. Increased inward NCX activity promotes cardiomyocyte depolarization, providing a mechanism for prolonged APs and increased ectopy in *Tbx5*-mutant atrial cardiomyocytes.

Genetic augmentation of SERCA activity and normalization of SR load eliminates susceptibility to AF {#s2-4}
---------------------------------------------------------------------------------------------------

We hypothesized that *Tbx5* deficiency reduces SERCA activity by decreasing SERCA2 protein expression ([Figure 4A](#fig4){ref-type="fig"}) and increasing expression of phospholamban (*Pln*), a negative regulator of SERCA2 ([Figure 1D](#fig1){ref-type="fig"}). If these were the primary causes of decreased SERCA function in *Tbx5*-mutant atria, reduced PLN or PLN phosphorylation (relieving inhibition of SERCA2) would be expected to normalize SERCA function. Western blot analysis showed that PLN expression was significantly increased in *Tbx5^fl/fl^;R26^CreERT2^* compared with *R26^CreERT2^* atria ([Figure 5A](#fig5){ref-type="fig"}). In addition, PLN phosphorylation was also increased at serine 16 in *Tbx5^fl/fl^;R26^CreERT2^* compared to *R26^CreERT2^*. These data suggest PLN phosphorylation may be a compensatory mechanism in response to decreased SERCA expression and activity, but is insufficient to normalize SERCA function ([Figure 4](#fig4){ref-type="fig"}). Thus, we hypothesized that reduction of *Pln* gene expression would be more effective in restoring SERCA function.

![Phospholamban knockout normalized SERCA function in *Tbx5^fl/fl^;R26^CreERT2^*.\
(**A**) PLN expression was increased in *Tbx5^fl/fl^;R26^CreERT2^* compared to *R26^CreERT2^* as measured by western blot with five animals per genotype. PLN expression was normalized to GAPDH. The proportion of PLN S16, but not T17 phosphorylation was also increased (normalized to PLN). (**B**) Representative SR load and SERCA measurements in *R26^CreERT2^, Tbx5^fl/fl^;R26^CreERT2^*, *Pln^-/-^;R26^CreERT2^*, *Tbx5^fl/fl^;Pln^-/+^;R26^CreERT2^* and *Tbx5^fl/fl^;Pln^-/-^;R26^CreERT2^* atrial cardiomyocytes were collected as described in [Figure 4](#fig4){ref-type="fig"}. (**C, D**) SR load and SERCA function were significantly higher in *Tbx5^fl/fl^;Pln^-/+^;R26^CreERT2^* and *Tbx5^fl/fl^;Pln^-/-^;R26^CreERT2^* compared to *Tbx5^fl/fl^;R26^CreERT2^* cardiomyocytes and comparable to *R26^CreERT2^* cardiomyocytes. (**E**) \[Ca^2+^\]~i~ transient peaks were unchanged in *Tbx5^fl/fl^;R26^CreERT2^*, *Tbx5^fl/fl^;Pln^-/+^;R26^CreERT2^* and *Tbx5^fl/fl^;Pln^-/-^;R26^CreERT2^*, but increased in *Pln^-/-^;R26^CreERT2^* cardiomyocytes. (**F**) \[Ca^2+^\]~i~ transient decay rate in *Tbx5^fl/fl^;Pln^-/+^;R26^CreERT2^* and *Tbx5^fl/fl^;Pln^-/-^;R26^CreERT2^* cardiomyocytes were normalized to that of *R26^CreERT2^* cardiomyocytes (myocytes/mice; n = 34/3 *R26^CreERT^*, n = 36/3 *Tbx5^fl/fl^;R26^CreERT2^,* n = 30/3 *Pln^-/-^;R26^CreERT2^*, n = *21*/3 *Tbx5^fl/fl^;Pln^-/+^;R26^CreERT2^, n = 27*/3 *Tbx5^fl/fl^;Pln^-/-^* atrial cardiomyocytes). (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001).\
10.7554/eLife.41814.023Figure 5---source data 1.Western blot for [Figure 5A](#fig5){ref-type="fig"}.\
10.7554/eLife.41814.024Figure 5---source data 2.Ca^2+^ Handling parameters for [Figure 5C--F](#fig5){ref-type="fig"}.](elife-41814-fig5){#fig5}

We assessed if *Pln* deficiency can affect SERCA function in a dose dependent manner by crossing the *Tbx5^fl/fl^;R26^CreERT2^* with germline *Pln* knockout mice (*Pln^-/-^;R26^CreERT2^*) ([@bib33]). We compared SR load and SERCA function in adult-specific *Tbx5; Pln* double mutant mice versus *Tbx5* mutant mice. We measured SR load and SERCA function using caffeine-induced SR release in atrial cardiomyocytes from *R26^CreERT2^, Tbx5^fl/fl^;R26^CreERT2^, Pln^-/-^;R26^CreERT2^*, *Tbx5^fl/fl^;Pln^-/+^;R26^CreERT2^* mice, and *Tbx5^fl/fl^;Pln^-/-^;R26^CreERT2^* mice. Control *Pln* deficient mice (*Pln^-/-^;R26^CreERT2^*) had increased steady state SR load and SERCA activity relative to *R26^CreERT2^* ([Figure 5C,D](#fig5){ref-type="fig"}). The decreased SR load and SERCA function observed in *Tbx5* mutant mice (*Tbx5^fl/fl^;R26^CreERT2^*) was converted to elevated SR load and SERCA function after the removal of *Pln* (*Tbx5^fl/fl^;Pln^-/-^; R26^CreERT2^)* ([Figure 5C,D](#fig5){ref-type="fig"}). *Pln* loss alone increased peak twitch calcium. However, in the setting of combined *Tbx5;Pln* deficiency, peak twitch calcium and tau twitch were normalized to *R26^CreERT2^* values ([Figure 5E,F](#fig5){ref-type="fig"}).

We next tested the possibility that decreased SERCA function was the mechanism of TBX5-deficiency-driven AP prolongation and triggered activity and that decreased *Pln* may rescue these defects. As we previously showed, *Tbx5^fl/fl^;R26^CreERT2^* atrial cardiomyocytes exhibited significantly prolonged APs and frequent EADs and DADs compared to *R26^CreERT2^* atrial cardiomyocytes ([Figure 6A,B](#fig6){ref-type="fig"}) ([@bib36]). APs of *Pln^-/-^;R26^CreERT2^* atrial cardiomyocytes were similar to *R26^CreERT2^* controls ([Figure 6C](#fig6){ref-type="fig"}). The prolonged AP duration observed *Tbx5^fl/fl^;R26^CreERT2^* was rescued in both *Tbx5^fl/fl^;Pln^+/-^;R26^CreERT2^* and *Tbx5^fl/fl^;Pln^-/-^;R26^CreERT2^* atrial cardiomyocytes (43 ± 10% and 38 ± 5% shorter than *Tbx5^fl/fl^;R26^CreERT2^* respectively; p=0.01, 0.0007) ([Figure 6D,E](#fig6){ref-type="fig"}). Along with normalization of AP duration, we observed significantly fewer EADs and DADs in *Tbx5^fl/fl^;Pln^-/-^;R26^CreERT2^* cardiomyocytes ([Figure 6F](#fig6){ref-type="fig"}). The data demonstrate the importance of TBX5-driven SERCA activity on cellular electrophysiology and triggered activity in atrial cardiomyocytes and decreased *Pln* rescues both SERCA function and cardiomyocyte electrophysiological abnormalities in *Tbx5*-mutant mice.

![PLN knockout normalized AP duration and prevented triggered activity in *Tbx5^fl/fl^;R26^CreERT2^*.\
Representative APs recorded from (**A**) *R26^CreERT2^*, (**B**)*Tbx5^fl/fl^;R26^CreERT2^,* (**C**)*Pln^-/-^;R26^CreERT2^*, (**D**)*Tbx5^fl/fl^;Pln^-/+^;R26^CreERT2^,* (**E**)*Tbx5^fl/fl^;Pln^-/-;^R26^*^CreERT2^*^* atrial cardiomyocytes as described previously in [Figure 2](#fig2){ref-type="fig"}. (**F**) TBX5-loss dependent AP prolongation and frequency of triggered activity was normalized by phospholamban knockout (myocytes/mice: n = 18/7 *R26^CreERT2^*, n = 24/12 *Tbx5^fl/fl^;R26^CreERT2^,* n = 12/5 *Pln^-/-^;R26^CreERT2^*, n = 9/3 *Tbx5^fl/fl^;Pln^-/+^;R26^CreERT2^, and n = 22*/3 *Tbx5^fl/fl^;Pln^-/-^;R26^CreERT2^*). (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001).\
10.7554/eLife.41814.026Figure 6---source data 1.AP Parameters for [Figure 6F](#fig6){ref-type="fig"}.](elife-41814-fig6){#fig6}

The data above show reducing *Pln* gene dosage rescues calcium handling defects, AP prolongation and triggered activity observed in *Tbx5*-mutant atrial cardiomyocytes. We hypothesized that normalizing these cardiomyocyte cellular defects would reduce AF susceptibility in *Tbx5* knockout mice ([Figure 7](#fig7){ref-type="fig"}). We performed intracardiac burst pacing. All *Tbx5^fl/fl^; R26^CreERT2^* mice (6/6) paced into AF, compared to none of the *R26^CreERT2^* (0/5) or *Pln^-/-^;R26^CreERT2^* littermate controls (0/7). Consistent with our hypothesis, AF susceptibility was significantly decreased in *Tbx5; Pln* compound knockouts: only 1/11 of *Tbx5^fl/fl^;Pln^-/-^;R26^CreERT2^* paced into AF ([Figure 7F](#fig7){ref-type="fig"}). Thus, *Tbx5-*deficiency induced AF is due to calcium handling abnormalities, specifically decreased SR load and SERCA activity, and that modulation of the SERCA2 inhibitor, *Pln*, normalized SERCA activity and AF susceptibility caused by *Tbx5* loss.

![PLN deficiency protected against TBX5-loss associated AF Intra-atrial pacing was used to induce AF.\
Representative intracardiac atrial electrogram recordings and corresponding surface ECG are shown from (**A**) *R26^CreERT2^*, (**B**)*Tbx5^fl/fl^;R26^CreERT2^,* (**C**)*Pln^-/-^;R26^CreERT2^*, (**D**)*Tbx5^fl/fl^;Pln^-/+^;R26^CreERT2^,* (**E**)*Tbx5^fl/fl^;Pln^-/-^;R26^CreERT2^* atrial cardiomyocytes. A, atrial electrical signal; V, far field ventricular electrical signal. (**F**) AF was reproducibly demonstrated in 6/6 *Tbx5* knockouts in contrast to 1/11 *Pln/Tbx5* double knockouts, indicating rescue of atrial arrhythmogenesis. P values were determined by Fisher's exact test (n = 5 *R26^CreERT2^*, n = 6 *Tbx5^fl/fl^;R26^CreERT2^,* n = 7 *Pln^-/-^;R26^CreERT2^*, and n = 5 *Tbx5^fl/fl^;Pln^-/+^;R26^CreERT2^, n* = 11 *Tbx5^fl/fl^;Pln^-/-^* mice).](elife-41814-fig7){#fig7}

Discussion {#s3}
==========

AF initiation has been linked to calcium handling abnormalities in computational and in vivo disease models ([@bib20]; [@bib22]). Ectopic or triggered activity in the form of EADs and DADs are often due to calcium handling abnormalities that increase NCX activity and promote AF initiation ([@bib22]). However, the mechanism underlying genetic predispositions for AF remain poorly understood. Genetic variants and mutations at the *Tbx5* locus are associated with increased risk for human AF and *Tbx5*-mutant mice show both spontaneous and burst pacing-induced AF ([@bib36]). We report a calcium transport mechanism for *Tbx5*-dependent ectopic activity. We show that TBX5 is a critical regulator of SERCA-mediated SR calcium handling and that *Tbx5*-deficient mice have increased NCX-mediated Ca^2+^ extrusion, balanced by increased I~CaL~ mediated Ca^2+^ influx. These calcium handling abnormalities provide a mechanism explaining the frequent triggered activity observed after TBX5 knockout. We show that decreasing phospholamban dosage can normalize TBX5-loss associated cellular calcium handling abnormalities, shorten AP duration, prevent triggered activity, and diminish AF susceptibility.

Decreased SERCA activity and SR load in TBX5-loss associated atrial fibrillation {#s3-1}
--------------------------------------------------------------------------------

We and others have hypothesized that ectopic triggers of AF can be due to abnormal atrial calcium handling ([@bib21]; [@bib4]). Here we define this relationship in a model of spontaneous AF. We analyzed the major calcium transport pathways in atrial myocytes and demonstrated that the critical calcium handling deficit associated with *Tbx5-*loss is depressed SERCA-mediated SR calcium uptake. We report significant reduction of SERCA2 protein expression and function, consistent with human paroxysmal or chronic AF ([@bib46]; [@bib47]; [@bib15]; [@bib8]).

The mechanism causing cardiomyocyte depolarizations from depressed SERCA activity must be indirect, given that SERCA2 is localized to the intracellular SR membrane and therefore does not directly contribute to membrane potential itself. Instead, slowed SR calcium uptake from depressed SERCA activity provides higher cytosolic calcium driving force for calcium extrusion from the cell via electrogenic inward I~NCX~.

Increased NCX activity in *Tbx5*- mutant atrial cardiomyocytes drives ectopic activity {#s3-2}
--------------------------------------------------------------------------------------

We demonstrate increased NCX1 protein expression with *Tbx5* knockout, a finding also observed in human and other animal models of AF ([@bib38]; [@bib27]; [@bib21]; [@bib15]). Since protein expression, electrochemical driving force, and allosteric calcium regulation can all affect amplitude of inward I~NCX~ ([@bib6]), we measured NCX activity following loss of *Tbx5*. NCX activity was significantly increased at all levels of calcium ([Figure 4I](#fig4){ref-type="fig"}). Thus, increased NCX function coupled with prolonged \[Ca^2+^\]~i~ transients, drives increased inward I~NCX~, providing additional depolarizing current during the AP, contributing to its prolongation. While increased NCX function may partially compensate for the depressed SERCA function to bring down calcium levels, it may also promote calcium-induced DADs in the setting of inappropriately timed SR calcium release events. Previous modeling in ventricular cardiomyocytes predicted countervailing functions of SERCA and NCX ([@bib28]), which we observed in *Tbx5* knockout mice. Our data further support that DADs, which are classically thought to relate to SR calcium overload can still occur with depressed SR loads in the appropriate context of depressed SERCA and elevated NCX function ([@bib46]).

Modeling suggests that compensatory increases in L-type calcium current in the setting of depressed SERCA function could be required to maintain systolic and diastolic calcium levels ([@bib28]). In line with the modeling, we observed enhanced peak I~CaL~ with loss of *Tbx5*. This may account for early AP prolongation as well as EADs. It is interesting that peak \[Ca\]~i~ is depressed using controlled square wave voltage clamp pulses ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), which suggests that 40 ms is insufficient to maintain calcium entry in *Tbx5* knockout, even in the setting of enhanced I~CaL~. However, in the setting of AP prolongation ([Figure 2E--G](#fig2){ref-type="fig"}) peak twitch calcium levels are maintained. Additionally, the increase in calcium entering the cell through I~CaL~ during the AP would be expected to balance a net increase in NCX mediated calcium extrusion ([Figure 4I](#fig4){ref-type="fig"}), a requirement for steady state \[Ca^2+^\]~i~ homeostasis. However, our observations that L-type calcium channel expression is TBX5-independent ([Figures 1D](#fig1){ref-type="fig"} and [2D](#fig2){ref-type="fig"}) and that genetically targeting only the Ca^2+^ efflux pathways in our model is sufficient to restore normal electrical activity ([Figures 5](#fig5){ref-type="fig"}--[7](#fig7){ref-type="fig"}) suggest that the I~CaL~ change is not a primary TBX5-dependent effect. Furthermore, although I~CaL~ is increased, it quickly inactivates in TBX5 knockout cardiomyocytes ([Figure 2F](#fig2){ref-type="fig"}). Together with our observation that nifedipine normalizes the APD, this supports that enhanced calcium entry impacts APD via secondary \[Ca\]~i~ dependent mechanisms.

TBX5 loss results in reduced RyR2 expression {#s3-3}
--------------------------------------------

In addition to identifying the role of altered NCX and SERCA function, we assessed the importance of TBX5-driven RyR2 expression. *RYR2* is a known susceptibility locus for AF and *RYR2* mutations are correlated with AF ([@bib16]; [@bib13]). We observed that RyR2 protein expression was significantly depressed following *Tbx5* loss . Defective RyR2 function has also been associated with AF ([@bib45]; [@bib25]). Despite TBX5-dependent RyR2 expression, the ryanodine binding assay ([@bib49]) suggested that RyR2 function is generally preserved over the physiologic range of calcium in *Tbx5*-mutant atria ([Figure 3D](#fig3){ref-type="fig"}). This suggests a compensatory mechanism must occur allowing for preserved RyR2 open probability in the setting of depressed protein expression. For example, CaMKII is a potential regulator of RyR2 function which could increase the open probability and thereby increase steady leakage or favor spontaneous local Ca^2+^ release events from the SR ([@bib45]; [@bib38]; [@bib19]) in *Tbx5*-deficient mice. In line with such compensation, we could not detect any differences in the calcium rise kinetics during controlled square wave voltage clamp pulses ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Nevertheless, RyR2 compensation in the setting of reduced expression could contribute to abnormal triggered activity in the setting of *Tbx5* loss, and is an important topic for further investigation.

Abnormalities of the TBX5/SERCA2/PLN regulatory axis drive AF formation {#s3-4}
-----------------------------------------------------------------------

We found that depressed SERCA function in TBX5 knockout was completely normalized with heterozygous or homozygous phospholamban knockout, which normalized AP duration, decreased frequency of afterdepolarizations, and reduced AF inducibility. This finding demonstrates the importance of SERCA2 to the pathophysiology of AF in the *Tbx5-*loss model. While phospholamban has been associated with AF by GWAS ([@bib16]; [@bib17]), its functional role is less clear. Although PLN is predominantly found in the ventricle ([@bib5]), we showed not only its expression is increased in the atria in the context of *Tbx5* loss, but also PLN participates in rheostatic control of SERCA activity in the atria, which is sufficient to protect against AF inducibility ([Figures 5](#fig5){ref-type="fig"}--[7](#fig7){ref-type="fig"}). Our findings are further supported by patient studies. For example, in patients who experience post-operative AF, SERCA2 is significantly decreased in the atrial tissue ([@bib51]), but those with PLN mutations have decreased AF susceptibility in the context of arrhythmogenic right ventricular cardiomyopathy ([@bib7]). Thus, AF is a heterogeneous disease and there can be variability in how the calcium handling proteins are expressed ([@bib12]) in different disease settings. The genetic background of an individual may be a critical determinant of how calcium handling moieties are disrupted to result in AF.

In summary, the most important features of the *Tbx5*-dependent SERCA2 and PLN regulatory axis are reduced SR uptake and load ([Figure 8](#fig8){ref-type="fig"}). In this setting, enhanced inward I~NCX~ and I~CaL~ contributes to AP prolongation, and, more importantly, to cardiomyocyte ectopy. Finally, we demonstrate PLN as a potential means to augment SERCA function, restoring normal atrial myocyte electrical activity and normal sinus rhythm in *Tbx5* knockout mice. Thus, the *Tbx5* knockout model represents an excellent system to study pharmacologic rescue of SERCA activity, prevention of cardiomyocyte ectopy, and AF.

![Model of TBX5-dependent calcium regulation in atrial cardiomyocytes.\
(**A**) Excitation-contraction coupling of atrial cardiomyocytes is achieved through regulation of intracellular calcium handling. (**B**) Adult-specific *Tbx5* knockout leads to decreased expression of SERCA2 and increased expression of PLN, leading to decreased SR Ca^2+^ load. In addition, removal of *Tbx5* is associated with increased NCX1 expression and activity, thereby increasing Ca^2+^ extrusion, which is balanced by increased L-type calcium entry. (**C**) Combined *Tbx5/Pln* knockout relieves repression of SERCA2. This results in normalization of SERCA activity and rescue of cardiomyocyte ectopy, triggered activity, and AF observed with *Tbx5* deficiency.](elife-41814-fig8){#fig8}

Broader implications for clinical treatment of AF {#s3-5}
-------------------------------------------------

AF has become an increasingly common cause of morbidity and mortality, underlying over one-third of stroke cases and significantly increases the risk for heart failure ([@bib39]). Consequently, AF poses a significant socioeconomic burden. AF does not always exist in isolation, but rather in conjunction with other predisposing factors such as obesity, thyroid hormone alterations, or heart failure. Interestingly, disruptions in calcium handling proteins such as the SERCA2-PLN regulatory axis are implicated as predisposing factors. In AF compounded by heart failure, decreased SERCA2 and phosphorylated PLN, and increased NCX1 expression were observed ([@bib32]). Decrease in phosphorylated PLN coupled with an increase in total PLN has been found in animal models of obesity, potentially increasing risk of AF ([@bib31]; [@bib30]). These findings suggest a need to evaluate an individual's genetic background as well as changes in calcium handling proteins when considering predisposing factors for AF.

Currently, there are few effective and targeted AF therapies, in part due to an incomplete understanding of the mechanisms underlying AF. Recent studies of specific genetic loci for AF susceptibility have opened new opportunities to identify specific mechanisms at play in subpopulations of AF patients. Understanding these specific mechanisms may facilitate more effective personalized therapies to target specific atrial Ca^2+^ handling abnormalities. Our data is consistent with the knowledge that pharmacologic regulators of NCX1 or SERCA2 may normalize defects in cellular calcium handling in the atrium ([@bib14]; [@bib24]; [@bib37]; [@bib18]; [@bib40]). For example, a selective NCX1 inhibitor, ORM-10103, was shown to prevent cellular Ca^2+^ handling abnormalities in ischemic ventricular cardiomyocytes, possibly by limiting calcium entry through outward I~NCX~ ([@bib24]; [@bib26]). The benefit of NCX inhibition might also be considered in human cases of AF with increased NCX activity. Further, resveratrol, which increases SERCA2 activity, has been shown to decrease AF, suggesting that targeting SERCA2 activity may be a viable therapeutic approach ([@bib3]; [@bib10]). In addition to providing specific insight into treating TBX5-loss associated AF, our findings may be more broadly applied. These data suggest that pharmacological treatment of AF may be improved by assessing for a defect in the TBX5-SERCA2-PLN axis followed by specifically targeting the defect to restore normal cardiomyocyte electrical activity. We expect this work and continued efforts to uncover mechanisms responsible for AF in subpopulations of patients will play a key role in advancing personalized therapeutics for AF.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\   Designation                                            Source or\                 Identifiers                  Additional\
  or resource                                                                      reference                                               information
  ------------------------- ------------------------------------------------------ -------------------------- ---------------------------- ----------------------------------------------------------
  Genetic reagent\          *Tbx5^fl/fl^* (*Tbx5*^tm1Jse^)                         PMID: 11572777, 27582060   MGI:2387850                  Dr. Jonathan G Seidman (Harvard)
  (M. musculus)                                                                                                                            

  Genetic reagent\          *Pln^-/-^* (*Pln*^tm1Egk^)                             PMID: 8062415              MGI:2158357                  Dr. Evangelia Kranias (University of Cincinnati)
  (M. musculus)                                                                                                                            

  Genetic reagent\          *Rosa26^CreERT2^*(*Gt(ROSA)26Sor*^tm1(cre/ERT2)Tyj^)   PMID: 17251932, 27582060   MGI:3790674                  Dr. Tyler Jacks (Massachusetts Insititute of Technology)
  (M. musculus)                                                                                                                            

  Antibody                  Mouse anti-RyR2                                        ThermoFisher               Cat. \#: MA3-925             WB (1:2000)

  Antibody                  Mouse anti-SERCA2                                      ThermoFisher               Cat. \#: MA3-919             WB (1:1000)

  Antibody                  Mouse anti-NCX                                         ThermoFisher               Cat. \#: MA3-926             WB (1:1000)

  Antibody                  Mouse anti-PLN                                         Badrilla                   Cat. \#: A010-14             WB (1:5000)

  Antibody                  Rabbit anti-pT17-PLN                                   Badrilla                   Cat. \#: A010-13             WB (1:5000)

  Antibody                  Rabbit anti-pS16-PLN                                   Badrilla                   Cat. \#: A010-12             WB (1:5000)

  Antibody                  Rabbit anti-Cav1.2                                     Alomone                    Cat. \#: ACC-003             WB (1:200)

  Antibody                  Mouse anti-GAPDH                                       Millipore                  Cat. \#: MAB374              WB (1:10000)

  Antibody                  Goat anti-mouse-HRP                                    Thermofisher               Cat. \#: 31437               WB (1:5000)

  Antibody                  Goat anti-rabbit-HRP                                   Thermofisher               Cat. \#: 31463               WB (1:5000)

  Chemical\                 Fluo-4 AM                                              Thermofisher               Cat. \#: 14201               10 µM x 20 min
  compound, drug                                                                                                                           

  Chemical\                 Nifedipine                                             Sigma                      Cat. \#: N7634               30 µM
  compound, drug                                                                                                                           

  Chemical\                 Collagenase Type 2                                     Worthington Biochemical    Cat. \# LS004177             1 g/L
  compound, drug                                                                                                                           

  Chemical\                 Tamoxifen                                              MP Biomedicals             Cat\#: 156738                2 mg/injection x three doses
  compound, drug                                                                                                                           

  Chemical\                 Laminin                                                Invitrogen                 Cat. \#: 2039175             0.5 mg/ml
  compound, drug                                                                                                                           

  Chemical\                 \[3H\]ryanodine                                        PerkinElmer                Cat. \#: NET950250UC         
  compound, drug                                                                                                                           

  Chemical\                 TRIzol                                                 Invitrogen                 Cat. \#: 15596026            
  compound, drug                                                                                                                           

  Chemical\                 Ryanodine                                              MP Biomedicals             SKU \#:0215377001            
  compound, drug                                                                                                                           

  Chemical\                 Caffeine                                               Sigma                      Cat. \#: C0750               10 mM
  compound, drug                                                                                                                           

  Software,\                Clampex/Clampfit Data acquisition and analysis         Molecular Devices          Version 10.3.2.1             
  algorithm                                                                                                                                

  Software,\                LabChart for electrophysiology\                        ADInstruments              Version 5 and 8              
  algorithm                 studies                                                                                                        

  Software,\                Buffering analyses using MaxChelator                   Stanford                   WEBMAXCLITE v1.15            Chris Patton, Stanford University
  algorithm                                                                                                                                

  Software,\                Western Blot quantification ImageJ                     NIH                        Version 1.48                 
  algorithm                                                                                                                                

  Software,\                Hierarchical Statistical technique using R             R Core Team                Script from PMID: 29016722   Ken Macleod, Imperial College London
  algorithm                                                                                                                                

  Commercial\               qScript cDNA synthesis kit                             Quanta                                                  
  Assay or Kit                                                                                                                             

  Commercial\               Power SYBR Green PCR Master Mix                        Applied Biosystems                                      
   Assay or Kit                                                                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Generation of mice {#s4-1}
------------------

The *Tbx5^fl/fl^*, *Pln^-/-^* and *Rosa26^CreERT2^* lines have all been previously described and were kept in a mixed genetic background ([@bib33]; [@bib9]; [@bib44]). Double knockout mice were generated by crossing *Tbx5^fl/fl^;R26^CreERT2^* mice with germline *Pln^-/-^* mice. After two generations, we obtained *Tbx5^fl/fl^;R26^CreERT2^* mice with either loss of one (*Pln^+/-^*) or both (*Pln^-/-^*) copies of *Pln*. All experiments were done using age- and genetic strain-matched littermate controls. Tamoxifen was administered for three consecutive days at a dose of 0.167 mg/kg body weight by intraperitoneal injection at 6--10 weeks of age, as previously described ([@bib36]). All experiments were performed in accordance to The University of Chicago Institutional Animal Care and Use Committee (IACUC) approved protocol.

ECG recordings {#s4-2}
--------------

8-to 10- week-old mice were anesthetized using isoflurane, and telemetry transmitters (ETA-F10, Data Science International) were implanted in the back with leads tunneled to the right upper and left lower thorax, as previously described (Wheeler MT et al., JCI 2004). Baseline recordings were obtained for 24 hr after a post-implant recovery period of one day. ECG data was analyzed using LabChart 8 (AD Instruments).

Intracardiac electrophysiology studies {#s4-3}
--------------------------------------

Detailed protocols for intracardiac electrograms have been previously described ([@bib36]). Briefly, 8- to 10- week-old mice were anesthetized with isoflurane and a vertical skin cut-down at the right jugular vein was performed. A 1.1 F octapolar catheter (EPR-800, Millar Instruments) was advanced in the right jugular vein to perform electrical stimulation. The catheter was connected to ADI BioAmp and PowerLab apparatus and signals were recorded using LabChart Software (ADInstruments). Atrial induction pacing was performed using burst pacing and the presence of at least three cycles of atrial tachycardia or fibrillation at least twice was considered positive.

\[Ca^2+^\]~i~ transient measurement {#s4-4}
-----------------------------------

Langendorff perfusion with 2 mg/mL of Collagenase Type 2 (Worthington Biochemical) at 5 ml/min was used to isolate atrial cardiomyocytes. Cardiomyocytes were then plated on laminin coated glass bottom dishes for 30 min prior to incubation with 10 µM Fluo-4/AM (Molecular Probes/Invitrogen) in normal Tyrode's solution containing (in mM): 140 NaCl, 4 KCl, 10 glucose, 10 HEPES, and 1 MgCl~2~, 1 CaCl~2~ pH 7.4 using NaOH for 20 min at room temperature. Cells were perfused with prewarmed Tyrode for 10 min prior to imaging. Imaging was performed on an Olympus microscope with a 20x objective lens, a LAMBDA DG-4 power source with 488 nm excitation and 515 nm emission filters and a PMT (photomultiplier tube) to record whole cell signal. Electrical field stimulation (Grass stimulator; Astro-Med) was performed at 1 Hz. SERCA and NCX measurements were performed by flowing sodium free Tyrode with 10 mM caffeine followed by sodium free Tyrode alone or Tyrode with caffeine respectively. Cells were returned to normal Tyrode in both cases at the end of the recording. \[Ca^2+^\]~i~ transients are presented as total fluorescence intensity normalized to resting fluorescence (F/F~0~) obtained from steady-state resting conditions before field stimulation. \[Ca^2+^\]~i~ transients and sparks were acquired in line-scan mode (3 ms per scan; pixel size 0.12 µm) using a Zeiss confocal microscope.

Whole-cell electrophysiological recordings {#s4-5}
------------------------------------------

APs and voltage clamp recordings were recorded using standard ruptured patch protocol ([@bib36]). We used current clamp mode with 0.5 nA ×2 ms current clamp pulses to measure APs. Voltage clamp mode was used to measure capacitance transients and to study \[Ca^2+^\]~i~ transients with fixed duration depolarizations. Cardiomyocytes are kept at 37°C and perfused with Tyrode solution (140 NaCl, 4 KCl, 1 MgCl~2~, 1 CaCl~2~, 10 HEPES, 10 Glucose, and pH 7.4 with NaOH). Internal pipette solution composition was (in mM): 20 KCl, 100 K-glutamate, 10 HEPES, 5 MgCl~2~, 10 NaCl, 5 Mg-ATP, 0.3 Na-GTP. Patch pipettes (World Precision Instruments) were pulled to have a mean resistance of 3.5--5 MΩ. An Ag--AgCl pellet and 3M KCl agar bridge was used to ground the bath. Liquid junction potentials, were always corrected after cell rupture.

External solution for I~CaL~ contained (in mM): 120 Tetraethylammonium-chloride, 10 CsCl, 10 Glucose, 10 HEPES, 1.5 MgCl~2~, 1 CaCl~2~, pH 7.4 with CsOH. Internal pipette solution contained (in mM): 100 Cs-methanesulfonate, 30 CsCl, 10 HEPES 5 EGTA, 2 MgCl~2~, 5 Mg-ATP, pH 7.2 with CsOH. I~CaL~ was recorded during 200 ms voltage clamp pulses from a holding potential of −40 mV to test potentials ranging from −40 to 60 mV, with pulses applied every 2 s in 5 mV increments. Peak current amplitudes were normalized to the cell capacitance (C~m~) and presented as current density (A/F). Steady-state inactivation of I~CaL~ was investigated using two-pulse protocol. Holding potential was −80 mV. The first pulse depolarized membrane from −60 to 20 mV with 10 mV increments during 500 ms, the second pulse depolarized the membrane to 10 mV for 50 ms. The inactivation curves were fit to a Boltzmann distribution.

Acquisition was performed using an Axopatch-200B amplifier connected to a Digidata1550A acquisition system (Axon Instruments, Foster City, CA, USA). In recording filtering at 2 kHz was performed using the amplifier Bessel and sampled at 10 kHz. Analysis was performed using pCLAMP10 (Axon Instruments) and a home written analysis code.

Western blots {#s4-6}
-------------

Atrial tissue was collected and homogenized as described previously ([@bib1]), in a buffer containing 0.9% NaCl, 10 mM Tris-HCl pH 6.8, 20 mM NaF and protease inhibitors. Equal amounts of protein, as determined by Bradford assay, were loaded. 50 µg of tissue homogenate, in Laemmli buffer, was separated by SDS-PAGE in 4--20% TGX or AnyKD precast gels (Bio-Rad). Proteins were transferred to PVDF membrane using the iblot2 transfer system (ThermoFisher) or wet transfer. Primary antibodies were as follows: anti-RyR2 (1:2000; MA3-925, ThermoFisher), SERCA2 (1:1000; MA3-919, ThermoFisher), NCX (1:1000; MA3-926, ThermoFisher), PLN (1:5000; A010-14, Badrilla), pT17-PLN (1:5000; A010-13, Badrilla), pS16-PLN (1:5000; A010-12, Badrilla), Cav1.2 (1:200; ACC-003, Alomone), GAPDH (1:10000; MAB374, Millipore). Secondary antibodies were: goat anti-mouse-HRP (1:5000; 31437, ThermoFisher) or goat anti-rabbit-HRP (1:5000; 31463, ThermoFisher). Secondary antibody concentrations were 5x higher when using the ibind Flex system. SuperSignal ECL reagent (ThermoFisher) was used to develop membranes followed by imaging with a ChemiDoc MP apparatus (Bio-Rad). Band intensities were quantified with the ImageLab software (Bio-Rad) or using ImageJ (NIH).

\[^3^H\]Ryanodine binding assay {#s4-7}
-------------------------------

Binding assays were carried out following a protocol previously described ([@bib17]). Binding mixtures contained 100 µg of protein from homogenates prepared from pooled atria (5--7 mice), 0.2 M KCl, 20 mM Hepes (pH 7.4), 6.5 nM \[^3^H\]ryanodine (PerkinElmer), 1 mM EGTA and enough CaCl~2~ to set free \[Ca^2+^\] between 10 nM (pCa^2+^ 8) and 100 µM (pCa^2+^ 4). The ratio between Ca^2+^ and EGTA was determined using MaxChelator (WEBMAXCLITE v1.15 <http://maxchelator.stanford.edu/webmaxc/webmaxclite115.htm>). Following a 2 hr incubation at 36°C, reactions were filtered through Whatman GF/B Filters using a Brandel M24-R Harvester. \[^3^H\]ryanodine binding was determined using a Beckman LS6500 scintillation counter and BioSafe II scintillation cocktail (RPI Corp). Non-specific binding was quantified in the presence of 2 µM unlabeled ryanodine (MP Biomedicals) and subtracted.

Quantitative real time PCR {#s4-8}
--------------------------

Left atrial tissue of *Tbx5^fl/fl^;R26^CreERT2^* and *R26^CreERT2^* mice was removed two weeks after receiving tamoxifen and RNA was isolated using a Trizol (Invitrogen) based method. Reverse transcription reaction was carried out using the qScript cDNA synthesis kit (Quanta) according to the manufacturer's protocol. Quantitative RT-PCR was performed using the Power SYBR Green PCR Master Mix (Applied Biosystems) and run on an Applied Biosystems AB7500 machine. Relative fold changes were calculated using the comparative threshold cycle method (2^-ΔΔCt^), using glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*) gene expression level as internal control.

PCR primers {#s4-9}
-----------

  Gene        F primer                   R primer
  ----------- -------------------------- -------------------------
  *Tbx5*      GGCATGGAAGGAATCAAGGT       CTAGGAAACATTCTCCTCCCTGC
  *Ryr2*      CAAATCCTTCTGCTGCCAAG       CGAGGATGAGATCCAGTTCC
  *Atp2a2*    CTGGTGATATAGTGGAAATTGCTG   GGTCAGGGACAGGGTCAGTA
  *Pln*       TTATGCCAGGACGGCAAAAG       CACTGTGACGATCACCGAAG
  *Sln*       CTGAGGTCCTTGGTAGCCTG       GGTGTGTCAGGCATTGTGAG
  *Cacna1c*   CTACAGAAACCCATGTGAGCAT     CAGCCACGTTGTCAGTGTTG
  *Ncx1*      TTCTCATACTCCTCGTCATCG      TTGAGGACACCTGTGGAGTG
  *Calm1*     TGGGAATGGTTACATCAGTGC      CGCCATCAATATCTGCTTCTCT
  *Calm2*     ACGGGGATGGGACAATAACAA      TGCTGCACTAATATAGCCATTGC
  *Calm3*     GATGGCACCATTACCACCAAG      CGCTGTCTGTATCCTTCATCTTT

Statistical analysis {#s4-10}
--------------------

Values are represented as mean ±standard error of the mean (±SEM). Statistical significance for quantitative metrics of APs, SERCA, NCX, SR load, I~CaL~, spark frequency, and \[Ca^2+^\]~i~ transients were determined using hierarchical statistical methods ([@bib42]). Statistical significance for mRNA, and protein expression studies was determined using Student's t-test. Statistical significance of the nifedipine effect on AP duration was determined using two-tailed paired t-test. A two-tailed Fisher's exact test was used for statistical significance of count-based analysis of AF inducibility and EAD and DAD count. Statistical significance is designated as \*p\<0.05, \*\*p\<0.01, and \*\*\*p\<0.001.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"A calcium transport mechanism for atrial fibrillation in Tbx5 mutant mice\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Richard Aldrich as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Robert S. Kass (Reviewer \#1); David Eisner (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. Our goal is to provide the essential revision requirements as a single set of instructions, so that you have a clear view of the revisions that are necessary for us to publish your work.

Summary:

This is an interesting study of the effects of the T-box transcription factor TBX5 on the susceptibility to atrial fibrillation (AF), the most common and difficult to treat human cardiac arrhythmia. The authors provide convincing evidence that knockout of *Tbx5* in adult mice leads to (1) decreased expression of the SR Ca^2+^ pump SERCA2 and increased expression of phospholamban, leading to a decreased level of SR Ca^2+^ loading; and (2) increased Na-Ca exchanger (NCX1) expression and activity, providing a mechanism for prolonged action potentials and triggered activity. Additional knockout of phospholamban restored normal SR loading and action potential duration and prevented triggered activity and AF in *Tbx5*-knockout mice. These results provide a mechanistic link from genetic (GWAS) studies to the cellular mechanisms of AF.

Essential revisions:

The reviewers all found the paper to be interesting and important, but raised a number of concerns that must be adequately addressed before it can be accepted. Some of the required revisions will require further experimentation within the framework of the presented studies and techniques.

1\) In Figure 2, the AP is lengthened in the *Tbx5* KO cells, and the effect of nifedipine to shorten the AP is greatly increased. The authors interpret this as an effect of prolonged and increased NCX current, but a change in Ca~v~1.2 activity may also contribute. Ca~v~1.2 channels could be more active in the KO cells if there is less Ca^2+^-dependent inactivation due to less CICR (from the reduced SR Ca content). This could contribute to the prolonged APD and to a more pronounced effect of nifedipine in blocking these channels. To address this point, the authors should conduct voltage clamp recordings of the Ca~v~1.2 current to monitor the degree of inactivation in WT vs. KO, with and without nifedipine. Simultaneous measurement of \[Ca^2+^\]~i~ would help establish a basis for these effects.

2\) The authors suggest that a larger NCX current occurs in the *Tbx5* KO cells because of an increased NCX and decreased SERCA, but this needs some qualification. In the steady state, the amount of Ca pumped out of the cell must balance influx through L-type channels (assuming negligible PMCA activity). Thus, changes in SERCA and NCX cannot affect the integral of the NCX current. If the long plateau of the action potential in Figure 2B reflects an increase of delayed NCX current (due to prolongation of the Ca^2+^ transient by decreased SERCA), then this must be associated with a decrease of NCX in the earlier stage of the action potential. Is there any evidence for this? As suggested above (\#1), simultaneous recording of the action potential and \[Ca^2+^\]~i~ in control and *Tbx5* KO cells would help to clarify this point.

3\) In Figure 4E, the lack of effect of *Tbx5* KO on the amplitude of the twitch Ca^2+^ transient is interesting given that SR Ca^2+^ content is decreased. Two potential compensatory mechanisms should be addressed. 1) It may be a consequence of the prolongation of the AP. Stimulation of the cells with constant-duration square voltage clamp pulses while measuring \[Ca^2+^\]~i~ (see \#1 above) would show whether the Ca transient is now less in *Tbx5* than control. 2) It looks as though, as a consequence of the slowing of decay of the Ca^2+^ transient (Figure 4F), the diastolic \[Ca^2+^\]~i~ is elevated. This may reduce cytoplasmic Ca^2+^ buffering such that a smaller total release of Ca^2+^ from the SR could result in an unchanged amplitude of the Ca^2+^ transient. Please comment on this possibility.

4\) The statistical analysis may need to be modified. In Figure 1, please state the actual numbers of animals used in each group and for the t test. In Figure 2, 3C, 4E-I, and 5C-F, unless each myocyte comes from a different heart, it is invalid to use the number of cells as the \"n\" values for the t test (see Lazic, BMC Neurosci 2010;11:5). Either use hierarchical or nested statistical approaches (e.g., Sikkel, Francis and Howard, et al. 2017) or simply average cells from the same heart and reduce n to be the number of hearts.

5\) Although PLB mRNA is increased in *Tbx5* KO mice, the functional contribution of PLB needs to be addressed by examining the phosphorylation status of PLB16 and PLB17.

6\) The role of increased NCX in causing AF in *Tbx5*-KO mice needs to be tested directly. Can an NCX inhibitor eliminate EADs and DADs in *Tbx5*-KO myocytes?

7\) The atrial phenotype of the *Tbx5* KO mouse (reduced RyR expression, increased NCX, reduced SERCA activity and SR Ca^2+^ load) are typical heart failure phenotypes. This raises the question of whether the observed phenotype indicates the underlying basis of AF, or is secondary to ventricular changes leading to heart failure. This question may be addressed using the mouse model before it has progressed to the heart failure stage.

10.7554/eLife.41814.032

Author response

> Essential revisions:
>
> The reviewers all found the paper to be interesting and important, but raised a number of concerns that must be adequately addressed before it can be accepted. Some of the required revisions will require further experimentation within the framework of the presented studies and techniques.
>
> 1\) In Figure 2, the AP is lengthened in the Tbx5 KO cells, and the effect of nifedipine to shorten the AP is greatly increased. The authors interpret this as an effect of prolonged and increased NCX current, but a change in Ca~v~1.2 activity may also contribute. Ca~v~1.2 channels could be more active in the KO cells if there is less Ca^2+^-dependent inactivation due to less CICR (from the reduced SR Ca content). This could contribute to the prolonged APD and to a more pronounced effect of nifedipine in blocking these channels. To address this point, the authors should conduct voltage clamp recordings of the Ca~v~1.2 current to monitor the degree of inactivation in WT vs. KO, with and without nifedipine. Simultaneous measurement of \[Ca^2+^\]~i~ would help establish a basis for these effects.

We agree with the reviewers that I~CaL~ could contribute to APD prolongation, and that calcium influx and efflux must be balanced. To address this, we have measured I~CaL.~ We find peak I~CaL~ is increased 92 ± 34% in *Tbx5^fl/fl^;R26^CreERT2^* cardiomyocytes in comparison to the *R26^CreERT2^* control. (new Figure 2E-G). Additionally, 30 μM nifedipine completely blocked I~Ca,L~ and eliminated any \[Ca^2+^\]~i~ transient in both TBX5 KO and control cardiomyocytes (new Figure 2---figure supplement 1). These data are consistent with a role of I~CaL~ in AP prolongation. Increased I~CaL~ may augment peak \[Ca\]~i~ in the setting of depressed SR load (Figure 4G) and also approximately balances the increase in NCX mediated calcium efflux (Figure 4I). We have added these observations to the Results and Discussion sections of the text.

> 2\) The authors suggest that a larger NCX current occurs in the Tbx5 KO cells because of an increased NCX and decreased SERCA, but this needs some qualification. In the steady state, the amount of Ca pumped out of the cell must balance influx through L-type channels (assuming negligible PMCA activity). Thus, changes in SERCA and NCX cannot affect the integral of the NCX current. If the long plateau of the action potential in Figure 2B reflects an increase of delayed NCX current (due to prolongation of the Ca^2+^ transient by decreased SERCA), then this must be associated with a decrease of NCX in the earlier stage of the action potential. Is there any evidence for this? As suggested above (\#1), simultaneous recording of the action potential and \[Ca^2+^\]~i~ in control and Tbx5 KO cells would help to clarify this point.

The reviewers correctly point out that calcium influx must match calcium efflux in steady state. We have now considered this point in the context of new experiments to determine I~CaL.~ Our new finding that increased NCX current is offset by increased I~CaL~ now can explain steady state \[Ca\]~i~ balance. We have included these data (Figure 1 and 2) and include corresponding discussions. Nevertheless, the reviewers also point out that a decrease in NCX in the earlier stage of the action potential could also contribute to steady state \[Ca\]~i~ balance. Indeed, in the setting of AP prolongation, a decreased electrochemical drive for inward I~NCX~ could exist in the early part of the AP. Therefore, as suggested by the reviewers, simultaneous AP and \[Ca^2+^\]~i~ measurements were performed (new Figure 1C). Peak \[Ca\]~i~ was not depressed during the AP, consistent with our field stimulation experiments in Figure 4E. Thus, assuming that submembrane calcium in the vicinity of the NCX is also similar, then the electrochemical drive for inward I~NCX~ may be decreased in the early part of the AP in *Tbx5^fl/fl^;R26^CreERT2^* cardiomyocytes relative to *R26^CreERT2^* control. However, in the context of increased I~CaL~ and I~NCX~ activity, it is challenging to dissect the individual contributions of calcium-dependent currents at depolarized potentials. In the future we hope to better quantify the influx and efflux pathways for calcium during the AP with *Tbx5* deficiency using a combined experimental and computer modeling approach. A discussion of this point has been added to the manuscript.

> 3\) In Figure 4E, the lack of effect of Tbx5 KO on the amplitude of the twitch Ca^2+^ transient is interesting given that SR Ca^2+^ content is decreased. Two potential compensatory mechanisms should be addressed. 1) It may be a consequence of the prolongation of the AP. Stimulation of the cells with constant-duration square voltage clamp pulses while measuring \[Ca^2+^\]~i~ (see \#1 above) would show whether the Ca transient is now less in Tbx5 than control. 2) It looks as though, as a consequence of the slowing of decay of the Ca^2+^ transient (Figure 4F), the diastolic \[Ca^2+^\]~i~ is elevated. This may reduce cytoplasmic Ca^2+^ buffering such that a smaller total release of Ca^2+^ from the SR could result in an unchanged amplitude of the Ca^2+^ transient. Please comment on this possibility.

The new square wave experiment proposed by the reviewers is a very good idea because it allows us to assess the peak \[Ca\]~i~ without the effect of AP prolongation. The square wave experiments are now shown in Figure 4---figure supplement 1. In these experiments *Tbx5^fl/fl^;R26^CreERT2^* cardiomyocytes have a 23 ± 4% decrease in the calcium transient amplitude compared to controls. Our results suggest that AP duration (possibly coupled with increased I~CaL~ density) can explain the similarities in peak twitch calcium between *Tbx5^fl/fl^;R26^CreERT2^* and *R26^CreERT2^* cardiomyocytes(Figure 4E). It is also interesting to consider that altered buffering capacity could play a role. However, we did not detect any changes in rate of rise of the first 10 ms of the calcium transient as would be expected if a greater portion of calcium buffer was bound or if total calcium buffering capacity was altered. (*R26^CreERT2^*riseslope = 107 ± 11 F/F~o~\*s; *Tbx5^fl/fl^;R26^CreERT2^*riseslope = 108 ± 18 F/F~o~\*s, p=0.96). Furthermore, we want to emphasize that F~o~ was always recorded at rest without pacing, so measurements of SR load would be unaffected by this possibility. This new data has been added to the manuscript.

> 4\) The statistical analysis may need to be modified. In Figure 1, please state the actual numbers of animals used in each group and for the t test. In Figure 2, 3C, 4E-I, and 5C-F, unless each myocyte comes from a different heart, it is invalid to use the number of cells as the \"n\" values for the t test (see Lazic, BMC Neurosci 2010;11:5). Either use hierarchical or nested statistical approaches (e.g., Sikkel, Francis and Howard, 2017) or simply average cells from the same heart and reduce n to be the number of hearts.

As suggested, we adjusted the statistical analysis using the hierarchical approach described in Sikkel et al \[1\]. Animal numbers are stated in the text where applicable and all of the figures are corrected to show significance indicators based on the revised analysis.

> 5\) Although PLB mRNA is increased in Tbx5 KO mice, the functional contribution of PLB needs to be addressed by examining the phosphorylation status of PLB16 and PLB17.

We agree that the phosphorylation status of PLN is important. Thus, we performed western blot for PLN-S16 and PLN-T17 in *Tbx5^fl/fl^;R26^CreERT2^*and *R26^CreERT2^* control atria. Phosphorylation of PLN-S16 was significantly increased while that of PLN-T17 was unchanged in *Tbx5^fl/fl^;R26^CreERT2^*compared to *R26^CreERT2^* control (Figure 5a). Increased S16 phosphorylation may be a compensatory mechanism for the decrease in SERCA expression. However, based on measurements of SERCA expression and activity (Figure 4A, H), functional effects of PLN phosphorylation are not sufficient to normalize SERCA activity, but knockout of *Pln* is sufficient (Figure 5). This data and related discussion have been added to the manuscript.

> 6\) The role of increased NCX in causing AF in Tbx5-KO mice needs to be tested directly. Can an NCX inhibitor eliminate EADs and DADs in Tbx5-KO myocytes?

As suggested by the reviewers, NCX inhibitors could theoretically reduce the frequency of DADs in our model. In our recordings using a new generation NCX inhibitor, ORM-10103, at 5μM, we observed a tendency towards action potential shortening (not significant) but no effect on frequency of triggered activity (EADs and DADs). A representative trace is shown in [Author response image 1A](#respfig1){ref-type="fig"}. However, very large I~NCX~ is still detectable in the presence of 5µM ORM-10103 using a square wave voltage clamp pulse to trigger SR release, as described in point 3 ([Author response image 1B](#respfig1){ref-type="fig"}). I~NCX~ inhibition was statistically insignificant (-4% ± 2%). Higher dosages of ORM-10103 or other NCX inhibitors are known to have off-target effects on Na^+^, Ca^2+^ and K^+^ channels, which would complicate interpretation \[2,3\], particularly in the setting of only partial NCX inhibition. Thus, it is unfortunately challenging to reach any conclusions from the NCX inhibitor data. As newer agents become available it would be reasonable to test their ability to inhibit triggered activity and AF in this model, and we address this in the Discussion.

[Author response image 1](#respfig1){ref-type="fig"}\>

![ORM-10103 does not reduce the frequency of DADs.\
(**A**) Simultaneous E~m~/\[Ca\]~i~ recordings demonstrate prolonged APs and presence of DADs (one highlighted in inset). (**B**) Tail currents recorded after 40 ms square wave voltage clamp pulses reveal uninhibited I~NCX~.](elife-41814-resp-fig1){#respfig1}

> 7\) The atrial phenotype of the Tbx5 KO mouse (reduced RyR expression, increased NCX, reduced SERCA activity and SR Ca^2+^ load) are typical heart failure phenotypes. This raises the question of whether the observed phenotype indicates the underlying basis of AF, or is secondary to ventricular changes leading to heart failure. This question may be addressed using the mouse model before it has progressed to the heart failure stage.

It is true that heart failure could complicate our interpretations. However, all experiments were performed at 2 weeks following tamoxifen injection. At this time point, the mice do not have any changes in ejection fraction, which begins after 3 weeks post-tamoxifen treatment \[4\].
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